Bevacizumab in the treatment of NSCLC: patient selection and perspectives

Bevacizumab in the treatment of NSCLC: patient selection and perspectives

Alessia E Russo,1 Domenico Priolo,1 Giovanna Antonelli,1 Massimo Libra,2 James A McCubrey,3 Francesco Ferraù1 1Medical Oncology Department, San Vincenzo Hospital, Taormina (Messina), Italy; 2Laboratory of Translational Oncology & Functional Genomics, Department of Biomedical and B...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Russo AE, Priolo D, Antonelli G, Libra M, Mccubrey JA, Ferraù F
Format: article
Langue:EN
Publié: Dove Medical Press 2017
Sujets:
bevacizumab
non-squamous NSCLC
eligibility
safety
subpopulations
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Accès en ligne:https://doaj.org/article/2a66d4dedbe34532a248193ff955aadc
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Internet

https://doaj.org/article/2a66d4dedbe34532a248193ff955aadc

Documents similaires